文章摘要
陈明祥,武正山,张信强,吕俊明,李 扬.胃癌患者血清IL-6、CA724、VEGF联合检测的临床意义[J].南京医科大学学报,2013,(2):247~250
胃癌患者血清IL-6、CA724、VEGF联合检测的临床意义
Clinical value of serum IL-6,CA724 and VEGF in patients with gastric cancer
投稿时间:2012-08-08  
DOI:10.7655/NYDXBNS20130223
中文关键词: 胃癌  肿瘤标志物  IL-6  CA724  VEGF  酶联免疫吸附试验
英文关键词: gastric cancer  tumor marker  IL-6  CA724  VEGF  ELISA
基金项目:
作者单位
陈明祥 仪征市人民医院肿瘤内科,江苏 仪征 211400 
武正山 仪征市人民医院肿瘤内科,江苏 仪征 211400 
张信强 仪征市人民医院肿瘤内科,江苏 仪征 211400 
吕俊明 仪征市人民医院肿瘤内科,江苏 仪征 211400 
李 扬 仪征市人民医院肿瘤内科,江苏 仪征 211400 
摘要点击次数: 1390
全文下载次数: 576
中文摘要:
      目的:研究胃癌患者血清白细胞介素-6(IL-6)?血清糖类抗原724(CA724)?血管内皮生长因子(vascular endothelial growth factor,VEGF)的检测在胃癌诊断中的临床意义。方法:采用ELISA 法测定80例胃癌患者及40例正常对照组血清IL-6?CA724?VEGF 的水平。结果:对照组患者血清IL-6?CA724?VEGF检测值均低于胃癌组[(48.12 ± 28.02) vs (149.62 ± 43.00)ng/ml,(4.53 ± 3.47) vs (15.29 ± 3.64)U/ml,(64.86 ± 17.67) vs (212.78 ± 125.61)pg/ml, P均< 0.01)]。胃癌患者血清IL-6?CA724?VEGF的联合检测的阳性率达到76.3%,明显高于各单项标记物的检测阳性率(分别为33.8%?43.8%?52.5%)。胃癌肝转移患者IL-6?CA724?VEGF检测值明显高于无肝转移患者[分别为(168.43 ± 54.03) vs (130.81 ± 10.00)ng/ml?(16.20 ± 4.57) vs (14.39 ± 2.05)U/ml?(289.47 ± 140.61) vs (136.09 ± 11.22)pg/ml,P 均< 0.05)],IL-6?CA724?VEGF 阳性率高于无肝转移患者(分别为50.0% vs 17.5%,P < 0.05;55.0% vs 32.5%,P > 0.05;65.0% vs 40.0%,P > 0.05)。结论:IL-6?CA724?VEGF 可用于胃癌及肝转移诊断?预后判断,联合检测可提高诊断率。
英文摘要:
      Objective: To investigate the clinical value of serum IL-6,CA724 and VEGF in gastric cancer patients. Methods:The serum levels of IL-6,CA724 and VEGF were detected with ELISA in 40 healthy subjects and 80 patients with gastric cancer. Results:The levels of three kinds of tumor markers in gastric cancer patients were obviously higher than those in the control group (IL:149.62 ± 43.00 vs 48.12 ± 28.02 ng/ml,CA724:15.29 ± 3.64 vs 4.53 ± 3.47 U/ml,VEGF:212.78 ± 125.61 vs 64.8 6±17.67 pg/ml,respectively,P < 0.01). Sensitivity of detection was improved when they were combined. The positive rate of IL-6,CA724 and VEGF in combination was 76.3%,which was significantly higher than that of single marker (33.8%,43.8% and 52.5%,respectively). The values of IL-6,CA724 and VEGF were also higher in gastric cancer patients with liver metastasis than those without such metastasis(168.43 ± 54.03 vs 130.81 ± 10.00 ng/ml,16.20 ± 4.57 vs 14.39 ± 2.05 U/ml,289.47 ± 140.61 vs 136.09 ± 11.22 pg/ml,P < 0.05). The positive rates of IL-6,CA724 and VEGF in gastric cancer patients with liver metastasis were remarkably higher than those in gastric cancer patients without liver metastasis(50.0% vs 17.5%,P < 0.05;55.0% vs 32.5%,P > 0.05;65.0% vs 40.0%,P > 0.05). Conclusion:The results suggested that the determination of serum IL-6,CA724 and VEGF is valuable for the diagnosis of gastric cancer and liver metastasis. The diagnostic value can be enhanced by detection of IL-6,CA724 and VEGF in combination.
查看全文   查看/发表评论  下载PDF阅读器
关闭